Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Northwest Bioth Cmn (NWBO)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ fieldTitles[key] ]] [[ value ]] [[ value ]]

Fundamentals

See More
  • Market Capitalization, $K 152,083
  • Shares Outstanding, K 517,290
  • Annual Sales, $ 340 K
  • Annual Income, $ -73,140 K
  • 36-Month Beta 1.56
  • Price/Sales 467.13
  • Price/Cash Flow N/A
  • Price/Book N/A
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -0.16
  • Most Recent Earnings N/A on N/A
  • Next Earnings Date 11/19/18
  • Annual Dividend & Yield 0.00 (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sectors:

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.1980 +34.65%
on 11/15/18
0.3151 -15.39%
on 12/11/18
+0.0686 (+34.65%)
since 11/14/18
3-Month
0.1750 +52.34%
on 09/24/18
0.3151 -15.39%
on 12/11/18
+0.0571 (+27.26%)
since 09/14/18
52-Week
0.1700 +56.82%
on 04/26/18
0.3980 -33.02%
on 01/16/18
-0.0032 (-1.19%)
since 12/14/17

Most Recent Stories

More News
NW Bio Announces That UK Property Transaction Has Closed, Including Funding of Approximately $47.3 Million Gross Proceeds

Northwest Biotherapeutics (OTCQB: NWBO) -- ("NW Bio"), a biotechnology company developing DCVax(R) personalized immune therapies for solid tumor cancers, announced that the package transaction involving...

NWBO : 0.2666 (-9.32%)
NW Bio Announces That UK Property Transaction Has Closed, Including Funding of Approximately $47.3 Million Gross Proceeds

BETHESDA, Md. , Dec. 14, 2018 /PRNewswire/ -- Northwest Biotherapeutics (OTCQB: NWBO) -- ("NW Bio"), a biotechnology company developing DCVax® personalized immune therapies for solid tumor cancers,...

NWBO : 0.2666 (-9.32%)
NW Bio Announces That UK Property Transaction Has Closed, Including Funding of Approximately $47.3 Million Gross Proceeds

Northwest Biotherapeutics (OTCQB: NWBO) -- ("NW Bio"), a biotechnology company developing DCVax® personalized immune therapies for solid tumor cancers, announced that the package transaction involving...

NWBO : 0.2666 (-9.32%)
NW Bio Announces Non-Dilutive Funding of Approximately $47.3 Million Through UK Property Transaction

Northwest Biotherapeutics (OTCQB: NWBO) -- ("NW Bio"), a biotechnology company developing DCVax(R) personalized immune therapies for solid tumor cancers, announced today that it has entered into agreements...

NWBO : 0.2666 (-9.32%)
NW Bio Announces Non-Dilutive Funding of Approximately $47.3 Million Through UK Property Transaction

Northwest Biotherapeutics (OTCQB: NWBO) -- ("NW Bio"), a biotechnology company developing DCVax® personalized immune therapies for solid tumor cancers, announced today that it has entered into agreements...

NWBO : 0.2666 (-9.32%)
Growth Opportunities in Stocks Coming Off of Bottoms

HENDERSON, NV / ACCESSWIRE / November 27, 2018 / With the market in a bit of a swoon, many companies with positive 3rd quarter announcements have not yet seen them baked into the share price properly....

VKTX : 8.99 (-3.44%)
EMHTF : 2.0300 (+1.50%)
NWBO : 0.2666 (-9.32%)
OGRMF : 3.6900 (+5.52%)
DCTH : 0.3481 (+2.38%)
Northwest Biotherapeutics Releases Phase III Data for DCVax(R)-L and Secures New Financing

NEW YORK, NY / ACCESSWIRE / November 26, 2018 / Traders News Source, a leading independent equity research and corporate access firm focused on small and mid-cap public companies is issuing a comprehensive...

NWBO : 0.2666 (-9.32%)
Updated Interim Data from Phase 3 Trial of DCVax®-L for Glioblastoma Presented at Society for Neuro-Oncology Conference

BETHESDA, Md. , Nov. 19, 2018 /PRNewswire/ -- Northwest Biotherapeutics (OTCQB: NWBO) -- ("NW Bio"), a biotechnology company developing DCVax® personalized immune therapies for solid tumor cancers,...

NWBO : 0.2666 (-9.32%)
Updated Interim Data from Phase 3 Trial of DCVax®-L for Glioblastoma Presented at Society for Neuro-Oncology Conference

Northwest Biotherapeutics (OTCQB: NWBO) -- ("NW Bio"), a biotechnology company developing DCVax® personalized immune therapies for solid tumor cancers, announced today that updated blinded interim data...

NWBO : 0.2666 (-9.32%)
Bigger Capital and District 2 Capital Issue White Paper in Support of DCVax-L, a Second-Generation Autologous Dendritic Cell Vaccine

Bigger Capital Fund, LP and District 2 Capital Fund LP, together with their affiliates (collectively, the "Funds"), hedge funds that invest primarily in biotechnology companies, announce that Carlo Rago,...

NWBO : 0.2666 (-9.32%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 16% Buy with a Weakest short term outlook on maintaining the current direction.

Longer term, the trend strength is Average. Long term indicators fully support a continuation of the trend.

See More Share

Trade NWBO with:

Key Turning Points

2nd Resistance Point 0.3162
1st Resistance Point 0.2914
Last Price 0.2666
1st Support Level 0.2479
2nd Support Level 0.2292

See More

52-Week High 0.3980
Fibonacci 61.8% 0.3109
Fibonacci 50% 0.2840
Last Price 0.2666
Fibonacci 38.2% 0.2571
52-Week Low 0.1700

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Read About Upcoming
Changes to This Feature
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar